Archemin

Advice & reporting for the chemical and pharmaceutical industries

Pact bewteen Patient and Pharmaceutical industry (Belgium)

Sun, 17/01/2016 - 8:16am -- Ludwig Everaert

Price competition for biosimilar medicinal products is considered an essential element in cost contaiment for the healthcare budget. Biosimilares are "copies of biological medicinal products for which the patent has expired,  the are comparable to generic medicines but in case of biosimilars, the active substance is not an exact copy of the originator product". For these products it has been shown that their effects in patients are similar to the originator product.

As part of the implementation of the Pact, on 7 January 2016, a convenant was signed by the Belgian Minister of Social Affairs and Public Health, Maggie De Block on the one hand and Pharma.be and Febelgen as representatives of the pharmaceutical industry on the other hand. The document acknowledges that although the therapeutic effects of biosimilars are equivalent to the originator, their production cost is lower. With this convenant, the Minister calls on healthcare professionals to prescribe more biosimilars in order to ensure the long-term viability and manageability of the Belgian healthcare system.

 

datum: 
Sunday, 17 January, 2016